Logo image of IMMX

IMMIX BIOPHARMA INC (IMMX) Stock Fundamental Analysis

NASDAQ:IMMX - Nasdaq - US45258H1068 - Common Stock - Currency: USD

1.76  -0.02 (-1.12%)

Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to IMMX. IMMX was compared to 571 industry peers in the Biotechnology industry. While IMMX seems to be doing ok healthwise, there are quite some concerns on its profitability. IMMX has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

IMMX had negative earnings in the past year.
IMMX had a negative operating cash flow in the past year.
In the past 5 years IMMX always reported negative net income.
In the past 5 years IMMX always reported negative operating cash flow.
IMMX Yearly Net Income VS EBIT VS OCF VS FCFIMMX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 -5M -10M -15M -20M

1.2 Ratios

With a Return On Assets value of -87.07%, IMMX is not doing good in the industry: 71.30% of the companies in the same industry are doing better.
Looking at the Return On Equity, with a value of -124.73%, IMMX is doing worse than 60.78% of the companies in the same industry.
Industry RankSector Rank
ROA -87.07%
ROE -124.73%
ROIC N/A
ROA(3y)-88.88%
ROA(5y)-116.56%
ROE(3y)-97.36%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
IMMX Yearly ROA, ROE, ROICIMMX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 0 50 -50 -100 -150 -200

1.3 Margins

IMMX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
IMMX Yearly Profit, Operating, Gross MarginsIMMX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023

More info and screens

6

2. Health

2.1 Basic Checks

IMMX has more shares outstanding than it did 1 year ago.
There is no outstanding debt for IMMX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
IMMX Yearly Shares OutstandingIMMX Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 5M 10M 15M
IMMX Yearly Total Debt VS Total AssetsIMMX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 5M 10M 15M

2.2 Solvency

Based on the Altman-Z score of -2.34, we must say that IMMX is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -2.34, IMMX is in line with its industry, outperforming 51.16% of the companies in the same industry.
IMMX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -2.34
ROIC/WACCN/A
WACCN/A
IMMX Yearly LT Debt VS Equity VS FCFIMMX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 0 5M -5M 10M -10M 15M

2.3 Liquidity

A Current Ratio of 3.47 indicates that IMMX has no problem at all paying its short term obligations.
IMMX's Current ratio of 3.47 is in line compared to the rest of the industry. IMMX outperforms 41.00% of its industry peers.
IMMX has a Quick Ratio of 3.47. This indicates that IMMX is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of IMMX (3.47) is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 3.47
Quick Ratio 3.47
IMMX Yearly Current Assets VS Current LiabilitesIMMX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 5M 10M 15M

More info and screens

1

3. Growth

3.1 Past

IMMX shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 7.22%.
EPS 1Y (TTM)7.22%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-4.35%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 38.87% on average over the next years. This is a very strong growth
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y2.64%
EPS Next 2Y4.96%
EPS Next 3Y16.25%
EPS Next 5Y38.87%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
IMMX Yearly Revenue VS EstimatesIMMX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 50M 100M 150M
IMMX Yearly EPS VS EstimatesIMMX Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 2 4 6

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for IMMX. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for IMMX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
IMMX Price Earnings VS Forward Price EarningsIMMX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
IMMX Per share dataIMMX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5

4.3 Compensation for Growth

IMMX's earnings are expected to grow with 16.25% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y4.96%
EPS Next 3Y16.25%

More info and screens

0

5. Dividend

5.1 Amount

IMMX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

IMMIX BIOPHARMA INC

NASDAQ:IMMX (2/21/2025, 8:00:01 PM)

1.76

-0.02 (-1.12%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-12 2024-11-12/amc
Earnings (Next)03-27 2025-03-27/amc
Inst Owners12.26%
Inst Owner Change-80.64%
Ins Owners28.49%
Ins Owner Change1.09%
Market Cap48.42M
Analysts82.86
Price Target7.14 (305.68%)
Short Float %2.04%
Short Ratio2.4
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-8.54%
Min EPS beat(2)-47.06%
Max EPS beat(2)29.97%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)-78.57%
EPS NQ rev (3m)-78.57%
EPS NY rev (1m)-31.25%
EPS NY rev (3m)-31.25%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)-50%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 2.76
P/tB 2.76
EV/EBITDA N/A
EPS(TTM)-0.88
EYN/A
EPS(NY)-0.79
Fwd EYN/A
FCF(TTM)-0.6
FCFYN/A
OCF(TTM)-0.57
OCFYN/A
SpS0
BVpS0.64
TBVpS0.64
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -87.07%
ROE -124.73%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-88.88%
ROA(5y)-116.56%
ROE(3y)-97.36%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 3832.79%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.47
Quick Ratio 3.47
Altman-Z -2.34
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)7.22%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-4.35%
EPS Next Y2.64%
EPS Next 2Y4.96%
EPS Next 3Y16.25%
EPS Next 5Y38.87%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-58.51%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-58.91%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-257.55%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-242.74%
OCF growth 3YN/A
OCF growth 5YN/A